AMGEN INC. DL-,0001/ US0311621009 /
2024-03-28 10:59:50 PM | Chg. -1.400 | Volume | Bid10:59:50 PM | Ask10:59:50 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
262.600EUR | -0.53% | - Turnover: - |
262.600Bid Size: - | 263.800Ask Size: - | 141.23 bill.EUR | - | - |
GlobeNewswire
03-25
Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate ...
GlobeNewswire
03-25
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Director...
GlobeNewswire
03-20
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
GlobeNewswire
03-18
NVIDIA Healthcare Launches Generative AI Microservices to Advance Drug Discovery, MedTech and Digita...
GlobeNewswire
03-18
Aspira Women’s Health Expands Senior Leadership Team with the Addition of Sandra Milligan, M.D., J.D...
GlobeNewswire
03-18
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Col...
GlobeNewswire
03-15
American Kidney Fund Announces 2024 Class of Corporate Members Providing Support in the Fight Agains...
GlobeNewswire
03-14
Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023
GlobeNewswire
03-12
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program...
GlobeNewswire
03-07
Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Busine...
GlobeNewswire
03-07
Oxford BioTherapeutics Announces Launch of Enhanced Discovery Platform, OGAP®-Verify, at World ADC C...
GlobeNewswire
03-06
TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business...